Prostate Cancer

In an interview with CURE at the Interdisciplinary Prostate Cancer Congress, Celesita Higano, M.D., discussed the early use of chemotherapy, the potential for PARP inhibitors and the evolving role of radium-223 in prostate cancer.

The amount of sleep a man gets can have an impact on prostate cancer outcomes, according to a recent study.

Nerve and other damage from cancer treatments can impair men’s sexual function, and adjusting can be a challenge.

Since it is found in the majority of patients with mCRPC, circulating tumor DNA may be able to lead the way to more personalized prostate cancer care.

Durvalumab and Lynparza (olaparib) provided a response for patients in a small study.

The Decipher test can be used to predict death and metastases in some patients with prostate cancer, according to findings that were recently presented.

Padeliporfin vascular-targeted photodynamic therapy may be a promising option for men with low-risk prostate cancer, according to the results of a recent study.

Adding hormone therapy to radiation therapy after surgery showed significant survival improvements in a recent study involving men with recurrent prostate cancer.

Findings from a recent study lay out the groundwork to help identify men who are at higher risk from dying of prostate cancer.

CURE spoke with David Albala, M.D., about the impact robotic surgery has had on patients with prostae cancer.

A recent study found that there has been a sharp decrease in the percentage of men who are being treated for prostate cancer.

A team of researchers at the University of Buffalo investigated the role that patients' stress and anxiety plays in deciding on treatment.

Chemotherapy agents such as docetaxel will remain a crucial part of treating patients with advanced prostate cancer, says William Oh, M.D.

Xofigo's role in the treatment of metastatic castration-resistant prostate cancer will continue to change.

When zoledronic acid use happens less frequently, patients with breast cancer, prostate cancer or multiple myeloma with bone metastases did not see an increase in skeletal-related events.

When cancer strikes, we all have weapons at hand with which to fight.

Adding Xtandi to Zytiga and prednisone did not improve progression-free survival for patients with metastatic castration-resistant prostate cancer, according to a recent study.

Ben Stiller is taking a stance in the debate over PSA screening.

Psilocybin, a component found in psychedelic mushrooms, reduced cancer-related anxiety and depression in a recent trial.

The National LGBT Cancer Network is making cancer screenings more available to a high-risk, underserved population.

Expert Howard I. Scher, M.D. discusses the future of liquid biopsy use for prostate cancer.

In prostate and other cancers, patient assistance programs can prevent drug costs from shaping treatment decisions.

Three recently-discovered molecular subtypes may help in crafting a more personalized treatment plan for men with prostate cancer.

Does PSA screening lead to an overtreatment of prostate cancer? Clayton S. Lau, M.D., discusses the topic.

An expert sat down with CURE to discuss standard therapies for localized prostate cancer.

Robotic surgery is a promising option in the field of prostate cancer, leading to better outcomes and shorter hospital stays.

Androgen deprivation therapy may be linked to dementia in men with prostate cancer, according to a recent study.